Marshall & Sullivan Inc. WA purchased a new position in Merck & Co., Inc. (NYSE:MRK) during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 2,450 shares of the company’s stock, valued at approximately $189,000.
A number of other large investors have also modified their holdings of MRK. Sowa Financial Group Inc. acquired a new stake in shares of Merck & Co., Inc. during the 4th quarter worth approximately $27,000. Total Clarity Wealth Management Inc. acquired a new stake in shares of Merck & Co., Inc. during the 4th quarter worth approximately $27,000. Stephenson National Bank & Trust acquired a new stake in shares of Merck & Co., Inc. during the 4th quarter worth approximately $28,000. CBIZ Investment Advisory Services LLC grew its stake in shares of Merck & Co., Inc. by 180.7% during the 1st quarter. CBIZ Investment Advisory Services LLC now owns 421 shares of the company’s stock worth $32,000 after purchasing an additional 271 shares during the period. Finally, Lion Street Advisors LLC acquired a new stake in shares of Merck & Co., Inc. during the 1st quarter worth approximately $35,000. Institutional investors own 74.26% of the company’s stock.
In other news, Director Wendell P. Weeks sold 5,000 shares of Merck & Co., Inc. stock in a transaction on Thursday, May 7th. The stock was sold at an average price of $76.02, for a total transaction of $380,100.00. Following the transaction, the director now owns 5,100 shares in the company, valued at approximately $387,702. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 0.28% of the stock is owned by insiders.
Shares of MRK stock opened at $77.36 on Tuesday. The stock’s fifty day moving average is $78.23 and its two-hundred day moving average is $81.08. The company has a debt-to-equity ratio of 0.82, a quick ratio of 0.87 and a current ratio of 1.11. The firm has a market capitalization of $193.67 billion, a P/E ratio of 19.58, a PEG ratio of 2.15 and a beta of 0.48. Merck & Co., Inc. has a fifty-two week low of $65.25 and a fifty-two week high of $92.64.
Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings data on Tuesday, April 28th. The company reported $1.50 earnings per share for the quarter, beating analysts’ consensus estimates of $1.34 by $0.16. The company had revenue of $12.06 billion for the quarter, compared to analyst estimates of $11.46 billion. Merck & Co., Inc. had a return on equity of 52.46% and a net margin of 21.10%. The firm’s revenue for the quarter was up 11.5% on a year-over-year basis. During the same quarter last year, the firm posted $1.22 EPS. On average, equities analysts forecast that Merck & Co., Inc. will post 5.3 earnings per share for the current year.
The business also recently declared a quarterly dividend, which was paid on Tuesday, July 7th. Stockholders of record on Monday, June 15th were issued a dividend of $0.61 per share. The ex-dividend date of this dividend was Friday, June 12th. This represents a $2.44 annualized dividend and a dividend yield of 3.15%. Merck & Co., Inc.’s dividend payout ratio is presently 47.01%.
A number of brokerages have recently commented on MRK. ValuEngine cut shares of Merck & Co., Inc. from a “hold” rating to a “sell” rating in a research note on Monday, June 8th. Guggenheim decreased their target price on Merck & Co., Inc. from $101.00 to $93.00 and set a “buy” rating on the stock in a research report on Wednesday, April 29th. Credit Suisse Group reiterated a “buy” rating and set a $95.00 target price on shares of Merck & Co., Inc. in a research report on Monday, May 4th. Morgan Stanley reiterated a “buy” rating and set a $89.00 target price on shares of Merck & Co., Inc. in a research report on Tuesday, June 23rd. Finally, UBS Group decreased their target price on Merck & Co., Inc. from $96.00 to $92.00 and set a “buy” rating on the stock in a research report on Monday, April 13th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and eleven have given a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $94.15.
Merck & Co., Inc. Profile
Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.
Featured Article: Yield Curve
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.